GRAIL, Inc. Common Stock —— 季度财务报表 (NASDAQ:GRAL)

展开完整图表

Financials

概览声明统计

每季度年度

Market Capitalization 2.1363 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry 诊断与研究

总收入

净利润

每股基本收益（基本 EPS）

总债务

自由现金流

现金及现金等价物

2.14 B 市值

市盈率

-7.7

市销率

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.